Change isn't a good thing for Japanese rheumatoid arthritis patients

August 09, 2020

Osaka, Japan - In many cases, a complex interplay between our genes and the environment governs whether or not we will develop a certain disease. Interestingly though, researchers are discovering that the genetic component of disease predisposition may depend on our ethnic background.

In a study published recently in Annals of the Rheumatic Diseases, a team of researchers led by Osaka University identified a genetic variant in the Japanese population that increases the likelihood of interstitial lung disease (ILD) among rheumatoid arthritis (RA) patients.

RA is an inflammatory autoimmune disease that primarily affects the joints but can also damage the heart, eyes, lungs, skin, and vascular system. ILD, a group of conditions characterized by fibrosis, or scarring, of the lung tissue, is one of the most common complications of RA and carries with it a significantly higher risk of death than uncomplicated RA.

"Previous studies have linked several genetic variants with an increased risk of ILD-complicated RA, but these risk variants do not hold for non-European populations," explains study lead author Yuya Shirai. "We therefore screened the genomes of almost 5,000 Japanese RA patients with and without ILD in search of novel genetic variants associated with ILD-complicated RA in the Japanese population."

Small variations in the sequence of a gene, often even a single nucleotide, can result in subtle changes in function. Using an approach called a genome-wide association study, the researchers found a variation at a single genetic locus on chromosome 7 that was more common among Japanese RA patients with ILD than those without.

"The genetic variant was also strongly associated with chest CT image patterns indicative of lung fibrosis and conferred a slightly increased risk of ILD in non-RA individuals," says Shirai.

More in-depth analysis revealed that the risk variant was located within a gene called RPA3, which previous studies have shown is essential for the cellular response to DNA damage and the regulation of telomeres, the regions at the ends of chromosomes that protect against degradation. One of the most common outcomes of telomere dysfunction is lung fibrosis.

"Based on our findings, we predict that the identified variant increases the risk of RA with ILD by altering the expression of RPA3, triggering fibrosis of the lung tissue," explains corresponding author Yukinori Okada. "Our study helps unravel the complicated etiology of RA, particularly among non-European patients, and may help further the development of personalized medicine for RA patients."
The article, "Association of the RPA3-UMAD1 locus with interstitial lung diseases complicated with rheumatoid arthritis in Japanese," was published in Annals of the Rheumatic Diseases at DOI:

About Osaka University

Osaka University was founded in 1931 as one of the seven imperial universities of Japan and is now one of Japan's leading comprehensive universities with a broad disciplinary spectrum. This strength is coupled with a singular drive for innovation that extends throughout the scientific process, from fundamental research to the creation of applied technology with positive economic impacts. Its commitment to innovation has been recognized in Japan and around the world, being named Japan's most innovative university in 2015 (Reuters 2015 Top 100) and one of the most innovative institutions in the world in 2017 (Innovative Universities and the Nature Index Innovation 2017). Now, Osaka University is leveraging its role as a Designated National University Corporation selected by the Ministry of Education, Culture, Sports, Science and Technology to contribute to innovation for human welfare, sustainable development of society, and social transformation. Website:

Osaka University

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to